Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients

References

• Sekijima Y . Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036–1043.
   PubMed Web of Science ®Google Scholar
• Araki S . Type I familial amyloidotic polyneuropathy (Japanese type). Brain Dev. 1984;6:128–133.
   PubMed Web of Science ®Google Scholar
• Schonhoft JD , Monteiro C , Plate L , et al. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci Transl Med. 2017.
   PubMed Web of Science ®Google Scholar
• Holmgren G , Ericzon BG , Groth CG , et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113–1116.
   PubMed Web of Science ®Google Scholar
• Coelho T , Maia LF , Martins da Silva A , et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–792.
   PubMed Web of Science ®Google Scholar
• Berk JL , Suhr OB , Obici L , et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;10:2658–2667.
   Google Scholar
• Coelho T , Adams D , Silva A , et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–829.
   PubMed Web of Science ®Google Scholar
• Ackermann EJ , Guo S , Benson MD , et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 2016;23:148–157.
   PubMed Web of Science ®Google Scholar
• Maia LF , Magalhaes R , Freitas J , et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86:159–167.
   PubMed Web of Science ®Google Scholar
• Sekijima Y , Yazaki M , Oguchi K , et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773–781.
   PubMed Web of Science ®Google Scholar
• Martins da Silva A , Cavaco S , Fernandes J , et al. Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. J Neurol. 2017;265:299–307.
   PubMed Web of Science ®Google Scholar
• Ando E , Ando Y , Okamura R , et al. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol. 1997;81:295–298.
   PubMed Web of Science ®Google Scholar
• Hara R , Kawaji T , Ando E , et al. Impact of liver transplantation on transthyretin-related ocular amyloidosis in Japanese patients. Arch Ophthalmol. 2010;128:206–210.
   PubMedGoogle Scholar
• Beirao JM , Malheiro J , Lemos C , et al. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015;22:117–122.
   PubMed Web of Science ®Google Scholar
• Dickson PW , Aldred AR , Marley PD , et al. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem Biophys Res Commun. 1985;127:890–895.
   PubMed Web of Science ®Google Scholar
• Soprano DR , Herbert J , Soprano KJ , et al. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem. 1985;260:11793–11798.
   PubMed Web of Science ®Google Scholar
• Cavallaro T , Martone RL , Dwork AJ , et al. The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest Ophthalmol Vis Sci. 1990;31:497–501.
   PubMed Web of Science ®Google Scholar
• Dwork AJ , Cavallaro T , Martone RL , et al. Distribution of transthyretin in the rat eye. Invest Ophthalmol Vis Sci. 1990;31:489–496.
   PubMed Web of Science ®Google Scholar
• Reiber H . Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001;310:173–186.
   PubMed Web of Science ®Google Scholar
• Eichenbaum JW , Zheng W . Distribution of lead and transthyretin in human eyes. J Toxicol Clin Toxicol. 2000;38:377–381.
   PubMed Web of Science ®Google Scholar
• Ingenbleek Y , Bernstein LH . Plasma transthyretin as a biomarker of lean body mass and catabolic states. Adv Nutr. 2015;6:572–580.
   PubMed Web of Science ®Google Scholar
• Ando Y , Tanaka Y , Nakazato M , et al. Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun. 1995;211:354–358.
   PubMed Web of Science ®Google Scholar
• Bulawa CE , Connelly S , Devit M , et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629–9634.
   PubMed Web of Science ®Google Scholar
• Rappley I , Monteiro C , Novais M , et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014;53:1993–2006.
   PubMed Web of Science ®Google Scholar
• Cho Y , Baranczak A , Helmke S , et al. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid. 2015;22:175–180.
   PubMed Web of Science ®Google Scholar
• Wiseman RL , Green NS , Kelly JW . Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry. 2005;44:9265–9274.
   PubMed Web of Science ®Google Scholar
• Choi S , Ong DS , Kelly JW . A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate. J Am Chem Soc. 2010;132:16043–16051.
   PubMed Web of Science ®Google Scholar
• Pardridge WM . CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13:963–975.
   PubMed Web of Science ®Google Scholar
• Sweeney MD , Sagare AP , Zlokovic BV . Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133–150.
   PubMed Web of Science ®Google Scholar
• Garai K , Posey AE , Li X , et al. Inhibition of amyloid beta fibril formation by monomeric human transthyretin. Protein Sci. 2018. DOI:10.1002/pro.3396
   PubMed Web of Science ®Google Scholar
• Li X , Song Y , Sanders CR , et al . Transthyretin suppresses amyloid-β secretion by interfering with processing of the amyloid-β protein precursor. J Alzheimers Dis. 2016;52:1263–1275.
   PubMed Web of Science ®Google Scholar
• Romero-Imbroda J, Sagrario-Fustero T, Del Canto-Pérez C. Tafamidis for a transplant patient with transthyretin amyloid polyneuropathy. J Clin Neurol. 2017;13:444–446.
   Google Scholar